Gilternib 40 mg (Giltertinib Furmarate)

Gilternib 40 mg (Gilteritinib): Targeted Therapy for FLT3-Mutated AML

Gilternib 40 mg is a precision oncology medication containing Gilteritinib, designed specifically for adult patients with relapsed or refractory Acute Myeloid Leukemia (AML) who harbor an FLT3 mutation. Unlike traditional chemotherapy, which affects both healthy and cancer cells, Gilternib 40 mg works as a targeted inhibitor, blocking the specific enzymes that drive leukemia cell growth.

Manufactured by Everest Pharmaceuticals Ltd., Gilternib 40 mg serves as an effective, high-quality generic alternative to Xospata, making advanced AML treatment more accessible globally.

Mechanism of Action: How Gilternib 40 mg Works

Gilternib 40 mg is a Tyrosine Kinase Inhibitor (TKI). In many AML cases, the FLT3 receptor (FMS-like tyrosine kinase 3) becomes mutated (specifically FLT3-ITD and FLT3-TKD mutations). These mutations act like a “stuck switch,” constantly signaling the bone marrow to produce abnormal leukemia cells.

Gilternib works by binding to this defective receptor and blocking its signaling pathways. This action stops the rapid proliferation of leukemic cells and induces programmed cell death (apoptosis). It also inhibits AXL, another kinase receptor often responsible for drug resistance, making it effective even where other treatments have failed.

Approved Indications and Usage

Gilternib 40 mg is prescribed for:

• Relapsed or Refractory AML: Adult patients whose cancer has returned or has not improved after previous treatments.

• FLT3-Mutated AML: Use requires confirmation of an FLT3 mutation (ITD or TKD) via an FDA-approved diagnostic test.

Dosage and Administration Guide

• Recommended Dose: The standard starting dose is 120 mg (three 40 mg tablets) taken orally once daily.

• Administration: Take the tablets at the same time each day, with or without food. Swallow tablets whole; do not break or crush.

• Missed Dose: If a dose is missed, take it as soon as possible on the same day (at least 12 hours before the next scheduled dose). Do not take two doses within 12 hours.

Safety Information: Warnings and Precautions

While Gilternib 40 mg is a life-extending therapy, it requires careful monitoring:

1. Differentiation Syndrome: A potentially life-threatening condition where leukemia cells release substances as they die/mature. Symptoms include fever, rapid weight gain, and difficulty breathing. Seek immediate medical attention if these occur.

2. QT Prolongation: This medication may affect heart rhythm. Regular ECG monitoring and electrolyte checks are required.

3. Side Effects: Common reactions include fatigue, elevated liver enzymes (ALT/AST), and muscle pain.

Generic Gilteritinib Price in Bangladesh

As a generic formulation manufactured in Bangladesh, Gilternib 40 mg offers significant cost savings compared to international brands.

Current Retail Price:

• Unit Price: Approx. ৳ 670.00 BDT (per tablet)

• Pack Price (30 Tablets): Approx. ৳ 20,100.00 BDT

(Note: Prices are subject to change by the manufacturer. International pricing in USD may vary based on exchange rates and shipping costs.)

Global Access via Onus Pharma

Onus Pharma is committed to bridging the gap between innovation and affordability. We supply Gilternib 40 mg to patients and healthcare providers worldwide (subject to local import regulations).

Why Choose Onus Pharma?

• Authenticity Guaranteed: Direct sourcing from Everest Pharmaceuticals.

• Global Logistics: Secure, temperature-controlled shipping to over 30 countries.

• Patient Support: 24/7 assistance with prescription verification and order tracking.

Need to order or request a quote? Contact us today to ensure timely access to this critical AML therapy.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. Treatment with Gilteritinib should only be initiated by a qualified oncologist.